Panacea Pharmaceuticals, based in Gaithersburg, Md., and Accelovance, a CRO headquartered in Rockville, Md., have established a clinical development services agreement to develop and advance Panacea's oncology immunotherapy pipeline. Accelovance will support Panacea's clinical development strategies by offering scientific/medical and regulatory experience, in addition to providing CRO support through project management, clinical monitoring, data management, biostatistics and safety services for Panacea's clinical trials.
Panacea will maintain stringent oversight and quality standards relating to patient safety and regulatory compliance, with Accelovance assisting with the development and implementation of clinical strategies. Panacea will rely on Accelovance's knowledge in the areas of vaccines, oncology and clinical management. Providing advanced insight into Panacea's development pipeline will enable both organizations to enhance operational planning, consistency and execution.